Literature DB >> 11154225

The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties.

M P Hardy1, C M Owczarek, S Trajanovska, X Liu, I Kola, P J Hertzog.   

Abstract

The ability to modify responses to type I interferons (IFNs) could alter processes such as hematopoiesis and immunity, which involve endogenous IFNs and responses to exogenous IFNs. The data presented here support a significant role for a recently identified soluble isoform of the murine type I IFN receptor, muIfnar-2a, as an efficient regulator of IFN responses. The messenger RNA (mRNA) transcript encoding muIfnar-2a is generally more abundant than that encoding the transmembrane isoform, muIfnar-2c. Furthermore, the ratio of muIfnar-2a:2c transcripts varied from more than 10:1 in the liver and other organs to less than 1:1 in bone-marrow macrophages, indicating independent regulation of the 2 transcripts encoding receptor isoforms and suggesting that the soluble muIfnar-2a levels are biologically relevant in some organs. Western blot analysis showed that soluble muIfnar-2 was present at high levels in murine serum and other biologic fluids and bound type I IFN. Recombinant muIfnar-2a competitively inhibited the activity of both IFNalpha and beta in reporter assays using the L929 cell line and in antiproliferative and antiviral assays using primary cells. Surprisingly, using primary thymocytes from Ifnar-2(-/-) mice, recombinant muIfnar-2a formed a complex with IFN alpha or beta and muIfnar-1 at the cell surface and transmitted an antiproliferative signal. These data indicate potential dual actions of soluble muIfnar-2 and imply that a signal can be transduced through the Ifnar-1 chain of the receptor complex in the absence of the cytoplasmic domain of Ifnar-2. Therefore, our results suggest that soluble Ifnar-2 is an important regulator of endogenous and systemically administered type I IFN.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11154225     DOI: 10.1182/blood.v97.2.473

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

Review 1.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

2.  Herpes simplex virus-1 infection causes the secretion of a type I interferon-antagonizing protein and inhibits signaling at or before Jak-1 activation.

Authors:  Karen E Johnson; David M Knipe
Journal:  Virology       Date:  2009-10-31       Impact factor: 3.616

3.  Impaired HCV clearance in HIV/HCV coinfected subjects treated with PegIFN and RBV due to interference of IFN signaling by IFNαR2a.

Authors:  Yu-Jin Lee; Xiaozhen Zhang; Estefania Vazquez; Gayathri Shivasabesan; Howard A Young; Alison Murphy; Honghui Wang; Anthony F Suffredini; Ulrich Siebenlist; Shyam Kottilil
Journal:  J Interferon Cytokine Res       Date:  2013-10-30       Impact factor: 2.607

Review 4.  Spontaneous germinal centers and autoimmunity.

Authors:  Phillip P Domeier; Stephanie L Schell; Ziaur S M Rahman
Journal:  Autoimmunity       Date:  2017-02       Impact factor: 2.815

5.  Multiple regions within the promoter of the murine Ifnar-2 gene confer basal and inducible expression.

Authors:  Matthew P Hardy; Paul J Hertzog; Catherine M Owczarek
Journal:  Biochem J       Date:  2002-07-15       Impact factor: 3.857

6.  Functional crosstalk between type I and II interferon through the regulated expression of STAT1.

Authors:  Daniel J Gough; Nicole L Messina; Linda Hii; Jodee A Gould; Kanaga Sabapathy; Ashley P S Robertson; Joseph A Trapani; David E Levy; Paul J Hertzog; Christopher J P Clarke; Ricky W Johnstone
Journal:  PLoS Biol       Date:  2010-04-27       Impact factor: 8.029

Review 7.  Interferons, signal transduction pathways, and the central nervous system.

Authors:  Shreeram C Nallar; Dhan V Kalvakolanu
Journal:  J Interferon Cytokine Res       Date:  2014-08       Impact factor: 2.607

8.  Type I interferons in the treatment of pancreatic cancer: mechanisms of action and role of related receptors.

Authors:  Giovanni Vitale; Casper H J van Eijck; Peter M van Koetsveld Ing; Joris I Erdmann; Ernst Jan M Speel; Katy van der Wansem Ing; Diana M Mooij; Annamaria Colao; Gaetano Lombardi; Ed Croze; Steven W J Lamberts; Leo J Hofland
Journal:  Ann Surg       Date:  2007-08       Impact factor: 12.969

9.  Transcriptional regulation of the human TRIF (TIR domain-containing adaptor protein inducing interferon beta) gene.

Authors:  Matthew P Hardy; Anne F McGGettrick; Luke A J O'Neill
Journal:  Biochem J       Date:  2004-05-15       Impact factor: 3.857

10.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.

Authors:  Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2009-07-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.